Comparison of RECIST to immune-related response criteria in patients with non-small cell lung cancer treated with immune-checkpoint inhibitors

Kim Hee Kyung; Heo Mi Hwa; Lee Han Sang; Sun Jong-Mu; Lee Se-Hoon; Ahn Jin Seok; Park Keunchil; Ahn Myung-Ju

首页> 外文期刊>Cancer chemotherapy and pharmacology. >Comparison of RECIST to immune-related response criteria in patients with non-small cell lung cancer treated with immune-checkpoint inhibitors

【24h】

Comparison of RECIST to immune-related response criteria in patients with non-small cell lung cancer treated with immune-checkpoint inhibitors

机译：用免疫检查点抑制剂治疗的非小细胞肺癌患者的免疫相关响应标准的比较

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Given that immune-related response in non-small cell lung cancer (NSCLC) has not been well evaluated, we assessed tumor response using the response evaluation criteria in solid tumors, version 1.1 (RECIST v1.1) and immune-related response criteria (irRC) to identify atypical responses in patients with advanced NSCLC treated with immunotherapeutic agents.

机译：鉴于非小细胞肺癌（NSCLC）的免疫相关反应尚未得到很好的评估，我们使用实体瘤的反应评估标准1.1版（RECIST v1.1）和免疫相关反应标准（irRC）来评估肿瘤反应，以确定接受免疫治疗剂治疗的晚期NSCLC患者的非典型反应。

著录项

来源
《Cancer chemotherapy and pharmacology.》 |2017年第3期|共8页
作者
Kim Hee Kyung; Heo Mi Hwa; Lee Han Sang; Sun Jong-Mu; Lee Se-Hoon; Ahn Jin Seok; Park Keunchil; Ahn Myung-Ju;
展开▼
作者单位

Sungkyunkwan Univ Samsung Med Ctr Dept Internal Med Div Hematol Oncol Sch Med 81 Irwon Ro;

Sungkyunkwan Univ Samsung Med Ctr Dept Internal Med Div Hematol Oncol Sch Med 81 Irwon Ro;

Sungkyunkwan Univ Samsung Med Ctr Dept Internal Med Div Hematol Oncol Sch Med 81 Irwon Ro;

Sungkyunkwan Univ Samsung Med Ctr Dept Internal Med Div Hematol Oncol Sch Med 81 Irwon Ro;

Sungkyunkwan Univ Samsung Med Ctr Dept Internal Med Div Hematol Oncol Sch Med 81 Irwon Ro;

Sungkyunkwan Univ Samsung Med Ctr Dept Internal Med Div Hematol Oncol Sch Med 81 Irwon Ro;

Sungkyunkwan Univ Samsung Med Ctr Dept Internal Med Div Hematol Oncol Sch Med 81 Irwon Ro;

Sungkyunkwan Univ Samsung Med Ctr Dept Internal Med Div Hematol Oncol Sch Med 81 Irwon Ro;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药理学;
关键词
Non-small cell lung cancer; Immune-checkpoint inhibitor; Immune-related response;

机译：非小细胞肺癌;免疫检查点抑制剂;免疫相关的反应;
入库时间 2022-08-20 17:03:14

相似文献

外文文献
中文文献
专利

1. Clinical characteristics and response to tyrosine kinase inhibitors of patients with non-small cell lung cancer harboring uncommon epidermal growth factor receptor mutations [J] . Yan Zhang, Zheng Wang, Xuezhi Hao, 中国癌症研究（英文版） . 2017,第001期
2. Survival without common toxicity criteria grade 3/4 toxicity following second-line treatment with pemetrexed for nonsquamous non-small cell lung cancer in Chinese patients [J] . WU Yi-long, SUN Yan, ZHOU Cai-cun, 中华医学杂志（英文版） . 2013,第024期
3. The Relationship Between THE PATHOLOGICAL CHANGES AND Response Rate (RR) IN Non-small Cell Lung Cancer Treated by Neoadjuvant Chemotherapy with Mitomycin (MMC), Vindesine (VDS) and Cisplatin (DDP) Combination [J] . 中国癌症研究（英文版） . 2000,第003期
4. Comparison of RECIST to immune-related response criteria in patients with non-small cell lung cancer treated with immune-checkpoint inhibitors [J] . Kim Hee Kyung, Heo Mi Hwa, Lee Han Sang, Cancer chemotherapy and pharmacology. . 2017,第3期

机译：用免疫检查点抑制剂处理的非小细胞肺癌患者的免疫相关响应标准的比较
5. Concordance between the response evaluation criteria in solid tumors version 1.1 and the immune-related response criteria in patients with non-small cell lung cancer treated with nivolumab: a multicenter retrospective cohort study [J] . Yuki Kataoka, Katsuya Hirano, Tomoko Narabayashi, Cancer chemotherapy and pharmacology. . 2018,第2期

机译：用Nivolumab处理的非小细胞肺癌患者的响应评估标准与实体瘤中的响应评估标准的一致性：多中心回顾性队列研究
6. Concordance between the response evaluation criteria in solid tumors version 1.1 and the immune-related response criteria in patients with non-small cell lung cancer treated with nivolumab: a multicenter retrospective cohort study [J] . Yuki Kataoka, Katsuya Hirano, Tomoko Narabayashi, Cancer chemotherapy and pharmacology. . 2018,第2期

机译：实体肿瘤版本1.1中的响应评估标准之间的一致性和用Nivolumab处理的非小细胞肺癌患者的免疫相关响应标准：多中心回顾性队列研究
7. Association between tumor heterogeneity and progression-free survival in non-small cell lung cancer patients with EGFR mutations undergoing tyrosine kinase inhibitors therapy [C] . Jiangdian Song, Di Dong, Yanqi Huang, Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2016

机译：接受酪氨酸激酶抑制剂治疗的EGFR突变非小细胞肺癌患者肿瘤异质性与无进展生存的关系
8. Assessing the effectiveness of palliative chemotherapy for non-small cell lung cancer: A phase IV study of patients treated at Ontario's cancer centres [D] . Harrison, Lyndsay Dawn. 2012

机译：评估姑息化疗对非小细胞肺癌的有效性：在安大略省癌症中心接受治疗的患者的IV期研究
9. Response criteria in solid tumors (PERCIST/RECIST) and SUVmax in early-stage non-small cell lung cancer patients treated with stereotactic body radiotherapy [O] . Cory Pierson, Taras Grinchak, Casey Sokolovic, 2018

机译：立体定向放射疗法治疗的早期非小细胞肺癌患者实体瘤的反应标准（PERCIST / RECIST）和SUVmax
10. P1.01-63 Correlation Between Immune-Related Adverse Events and Efficacy of Immune-Checkpoint Inhibitors in Patients with Non-Small Cell Lung Cancer [O] . M. Riudavets Melià, I. Gabriela Sullivan, A. Barba Joaquín, 2018

机译：P1.01-63非小细胞肺癌患者免疫相关不良事件与免疫检查点抑制剂的疗效相关的相关性
11. Phase 1 Trial of an Immune Checkpoint Inhibitor plus Stereotactic Ablative Radiotherapy in Patients with Inoperable Stage I Non-Small Cell Lung Cancer. [R] . Kelly, K., Monjazeb, A., Daly, M., 2017

机译：免疫检查点抑制剂加立体定向消融放疗治疗不能手术的I期非小细胞肺癌的1期试验。

Comparison of RECIST to immune-related response criteria in patients with non-small cell lung cancer treated with immune-checkpoint inhibitors

摘要

著录项

相似文献

相关主题

期刊订阅